Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25597122 | 0.86 | BRD4 (0.35) | BRD4GABRA1LMNAGABRB2GABRG2 | |
| SCHEMBL22022005 | 0.80 | BRD4 (0.37) | BRD4FAAHTSHR | |
| SCHEMBL16746110 | 0.76 | BRD4 (0.32) | BRD4HSP90AA1HSP90AB1HSP90B1 | |
| SCHEMBL2005190 | 0.74 | BRD4 (0.41) | BRD4LMNACA1CA2HIF1A | |
| SCHEMBL16698860 | 0.74 | BRD4 (0.41) | BRD4 | |
| SCHEMBL8098549 | 0.74 | BRD4 (0.45) | BRD4CA1CA2CYP1A2TSHR | |
| SCHEMBL17240950 | 0.73 | BRD4 (0.35) | BRD4LMNATSHRPTGS1HIF1A | |
| SCHEMBL6124120 | 0.72 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1HSP90B1 | |
| SCHEMBL21914103 | 0.72 | GABRA1 (0.37) | GABRA1GABRB2HSP90AA1HSP90AB1HSP90B1 | |
| SCHEMBL2005193 | 0.71 | BRD4 (0.42) | BRD4LMNACA1CA2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2022135470-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022094271-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220062296-A1 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-13 | — | — | US | disclosed |
| US-9533986-B2 | Bicyclic dihydropyridone kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-9469654-B2 | Bicyclic oxa-lactam kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150266871-A1 | BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9040530-B2 | 1,2,4-triazine-6-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | BRD4 123/4885GABRA1 2677/4885LMNA 4281/4885 |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | BRD4 3499/4885GABRA1 2292/4885LMNA 3006/4885 |
| US-20150266871-A1 | BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS | SYK, JAK2, ZAP70 | BRD4 370/4885GABRA1 1058/4885LMNA 4542/4885 |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | SYK, BTK, JAK2 | BRD4 601/4885GABRA1 1343/4885LMNA 4511/4885 |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | SYK, LCK, BTK | BRD4 1222/4885GABRA1 2476/4885LMNA 3173/4885 |
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | BRD4 410/4885GABRA1 3/4885LMNA 2588/4885 |
| US-20220062296-A1 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA2 | BRD4 3419/4885GABRA1 9/4885LMNA 2165/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | BRD4 882/4885GABRA1 3975/4885LMNA 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.